300026.SZ

Aug 25, 2026, 08:23 UTC

Hongri Pharmaceutical announced its 2026 half-year results: revenue of 2.188 billion yuan, down 21.72% year-on-year; net profit attributable to shareholders of 78.0889 million yuan, down 0.69% year-on-year; non-recurring net profit of 80.7153 million yuan, up 16.67% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.